State Street Corp Magenta Therapeutics, Inc. Transaction History

State Street Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$1.26 - $2.09 $15,750 - $26,125	12,500 Added 9.87%	139,207 $196,000
Q2 2022 Aug 15, 2022	SELL	$0.97 - $3.08 $412,687 - $1.31 Million	-425,451 Reduced 77.05%	126,707 $152,000
Q1 2022 May 16, 2022	SELL	$2.55 - $5.23 $65,098 - $133,516	-25,529 Reduced 4.42%	552,158 $1.6 Million
Q4 2021 Feb 14, 2022	BUY	$4.43 - $8.33 $182,533 - $343,229	41,204 Added 7.68%	577,687 $2.56 Million
Q3 2021 Nov 15, 2021	BUY	$6.07 - $9.89 $467,657 - $761,965	77,044 Added 16.77%	536,483 $3.91 Million
Q2 2021 Aug 16, 2021	BUY	$9.76 - $14.15 $950,975 - $1.38 Million	97,436 Added 26.92%	459,439 $4.49 Million
Q1 2021 May 17, 2021	BUY	$7.66 - $13.38 $11,804 - $20,618	1,541 Added 0.43%	362,003 $4.29 Million
Q4 2020 Feb 16, 2021	BUY	$6.1 - $7.94 $35,959 - $46,806	5,895 Added 1.66%	360,462 $2.83 Million
Q3 2020 Nov 10, 2020	SELL	$6.52 - $8.94 $49,089 - $67,309	-7,529 Reduced 2.08%	354,567 $2.41 Million
Q2 2020 Aug 14, 2020	BUY	$6.18 - $10.76 $50,249 - $87,489	8,131 Added 2.3%	362,096 $2.72 Million
Q1 2020 May 11, 2020	BUY	$6.03 - $15.24 $2.13 Million - $5.39 Million	353,965 New	353,965 $2.22 Million

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.